Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies
Abstract Severe acquired respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease (COVID-19). In severe COVID-19 cases, higher antibody titers against seasonal coronaviruses have been observed than in mild cases. To investigate antibody cross-reactivity as potential explanation for severe disease, we determined the kinetics, breadth, magnitude and level of cross-reactivity of IgG against SARS-CoV-2 and seasonal CoV nucleocapsid and spike from 17 severe COVID-19 cases at the clonal level. Although patients mounted a mostly type-specific SARS-CoV-2 response, B-cell clones directed against seasonal CoV dominated and strongly increased over time. Seasonal CoV IgG responses that did not neutralize SARS-CoV-2 were boosted well beyond detectable cross-reactivity, particularly for HCoV-OC43 spike. These findings support a back-boost of poorly protective coronavirus-specific antibodies in severe COVID-19 patients that may negatively impact de novo SARS-CoV-2 immunity, reminiscent of original antigenic sin..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 20. Okt. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Westerhuis, Brenda M. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.10.10.20210070 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019093217 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019093217 | ||
| 003 | DE-627 | ||
| 005 | 20230429091811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201014s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.10.20210070 |2 doi | |
| 035 | |a (DE-627)XBI019093217 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.10.10.20210070 | ||
| 035 | |a (biorXiv)10.1101/2020.10.10.20210070 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Westerhuis, Brenda M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Severe acquired respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease (COVID-19). In severe COVID-19 cases, higher antibody titers against seasonal coronaviruses have been observed than in mild cases. To investigate antibody cross-reactivity as potential explanation for severe disease, we determined the kinetics, breadth, magnitude and level of cross-reactivity of IgG against SARS-CoV-2 and seasonal CoV nucleocapsid and spike from 17 severe COVID-19 cases at the clonal level. Although patients mounted a mostly type-specific SARS-CoV-2 response, B-cell clones directed against seasonal CoV dominated and strongly increased over time. Seasonal CoV IgG responses that did not neutralize SARS-CoV-2 were boosted well beyond detectable cross-reactivity, particularly for HCoV-OC43 spike. These findings support a back-boost of poorly protective coronavirus-specific antibodies in severe COVID-19 patients that may negatively impact de novo SARS-CoV-2 immunity, reminiscent of original antigenic sin. | ||
| 700 | 1 | |a Aguilar-Bretones, Muriel |e verfasserin |4 aut | |
| 700 | 1 | |a Raadsen, Matthijs P. |e verfasserin |4 aut | |
| 700 | 1 | |a de Bruin, Erwin |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M.A. |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L. |e verfasserin |4 aut | |
| 700 | 1 | |a Langerak, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Endeman, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a van den Akker, Johannes P.C. |e verfasserin |4 aut | |
| 700 | 1 | |a Gommers, Diederik A.M.P.J. |e verfasserin |4 aut | |
| 700 | 1 | |a van Gorp, Eric C.M. |e verfasserin |4 aut | |
| 700 | 1 | |a Rockx, Barry H.G. |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P.G. |e verfasserin |4 aut | |
| 700 | 1 | |a van Nierop, Gijsbert P. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 20. Okt. |
| 773 | 1 | 8 | |g year:2020 |g day:20 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.10.20210070 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 20 |c 10 | ||
| 953 | |2 045F |a 570 | ||